Portage Biotech Soars 17.19% on Promising Preclinical Data

On April 18, 2025, Portage Biotech's stock surged by 17.19% in pre-market trading, reflecting a significant upward momentum.

Portage Biotech's stock price has been on a notable upward trajectory, driven by promising preclinical data on PORT-7, which demonstrated strong antitumor effects in mesothelioma. This development has sparked investor interest and optimism about the company's future prospects, particularly in advancing plans for clinical trials.

The company's focus on researching and developing pharmaceutical and biotech products has positioned it as a key player in the biotechnology industry. With a market cap of $10.3 million, Portage Biotech continues to attract attention from investors looking for growth opportunities in the healthcare sector.